Avalo Therapeutics (NASDAQ:AVTX) Receives New Coverage from Analysts at HC Wainwright

Equities research analysts at HC Wainwright assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The brokerage set a “neutral” rating on the stock.

Avalo Therapeutics Trading Up 9.4 %

Shares of AVTX stock opened at $14.44 on Thursday. Avalo Therapeutics has a 1 year low of $3.95 and a 1 year high of $34.46. The firm’s 50 day moving average is $9.47 and its 200-day moving average is $11.26.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Monday, August 12th. The company reported ($14.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Equities research analysts anticipate that Avalo Therapeutics will post -7.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avalo Therapeutics

Large investors have recently modified their holdings of the stock. Affinity Asset Advisors LLC acquired a new position in shares of Avalo Therapeutics during the first quarter worth approximately $218,000. Ikarian Capital LLC acquired a new position in shares of Avalo Therapeutics during the first quarter worth approximately $1,015,000. Finally, Logos Global Management LP bought a new stake in shares of Avalo Therapeutics during the second quarter worth approximately $6,722,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.